Skip to main content
. 2024 Jan 5;15(1):10. doi: 10.1038/s41419-023-06303-z

graphic file with name 41419_2023_6303_Figa_HTML.jpg

Novel dual PARP and HDAC inhibitors induce BRCAness to restore synthetic lethality, activating tumoral IFN signaling via the cGAS–STING pathway and inducing cytokine production, promoting neoantigen generation and presentation to enhance the immune response.